Anti-VEGF combined with Verteporfin photodynamic therapy in age-related macular degeneration(AMD)
Not Applicable
- Conditions
- Age-related Macular Degeneration
- Registration Number
- JPRN-UMIN000002128
- Lead Sponsor
- Yamagata University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
subjects with systemic risk factors
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the anti-VEGF and verteporfin combination in AMD treatment?
How does anti-VEGF plus photodynamic therapy compare to monotherapy in neovascular AMD outcomes?
Which biomarkers correlate with response to anti-VEGF and verteporfin combination therapy in AMD?
What are the long-term safety profiles of anti-VEGF combined with verteporfin in AMD patients?
Are there alternative combination therapies to anti-VEGF plus photodynamic therapy for geographic atrophy?